Tocilizumab: Molecular intervention therapy in children with systemic juvenile idiopathic arthritis

Expert Review of Clinical Immunology

Volumn 6, Issue 5, 2010, Pages 735-743

  Yokota, Shumpei ^a   Kishimoto, Tadamitsu ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

biologic response modifier; C reactive protein; IL 6; IL 6 receptor; systemic juvenile idiopathic arthritis; tocilizumab

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; TOCILIZUMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HUMAN; ILLNESS BEHAVIOR; IMMUNOPATHOGENESIS; INFECTION; JOINT DESTRUCTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY DIAGNOSIS; MACROPHAGE ACTIVATION SYNDROME; MORBIDITY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; TREATMENT DURATION;

ANAPHYLAXIS; ANEMIA; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFECTION; RECEPTORS, INTERLEUKIN-6;

EID: 77956526510     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.41     Document Type: Review

References (61)

1. th Edition). Cassidy JT, Petty RE (Eds). WB Saunders, PA, USA, 291-303 (2005).
2. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic fndings on liver biopsy illustrating the key role of activated IFN-y-producing lymphocytes and IL-6-and TNF-a-producing macrophages. Blood 105, 1648-1651 (2005).
3. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 41, 1444-1449 (2002).
4. Pascual V, Allantaz F, Patel P et al How the study of children with rheumatic diseases identifed interferon a and interleukin 1 as novel therapeutic targets. Immunol. Rev. 223, 39-59 (2008).
5. Vastert SJ, van Wijk R, D'Urbano LE et al Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 49, 441-449 (2010).
6. De Jager W, Vastert SJ, Beekman JM et al Defective phosphorylation of interleukin-18 receptor b causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2782-2793 (2009).
7. De Benedetti F, Massa M, Robbioni P. Correlation of interleukin-6 levels with joint involvement and thrombocytosis in patients with systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34, 1158-1163 (1991).
8. Lieskovska J, Guo D, Derman E. Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA. Growth Horm. IGF Res. 13, 26-35 (2003).
9. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new development in the understanding of the pathophysiology and therapy. Best Pract. Res. Clin. Rheumatol 23, 655-664 (2009).
10. Harden LM, du Plessis I, Poole S et al Interleukin (IL)-6 and IL-1p act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav. Immun. 22, 838-849 (2008).
11. Raj DSC. Role of interleukin-6 in the anemia of chronic disease. Semin. Arthritis Rheum. 38, 382-388 (2009).
12. Fournier T, Medjoubi-N N, Porquet D. a-1-acid glycoprotein. Biochim. Biophys. Acta 1482, 157-171 (2000).
13. Hagihara K, Nishikawa T, Sugamata Y et al Essential role of STAT3 in cytokine-driven NF-KB-mediated serum amyloid A gene expression. Genes Cells 10, 1051-1063 (2005).
14. Nishikawa T, Hagihara K, Serada S et al Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1a is essential for cytokine-driven C-reactive protein gene expression. J. Immunol. 180, 3492-3501 (2008).
15. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fuid and serum of patients with rheumatoid arthritis and other infammatory arthritides. Arthritis Rheum. 31, 784-788 (1988).
16. Yoshizaki K, Matsuda T, Nishimoto N et al Pathogenic signifcance of interleukin-6 (IL-6/BSF-2) in Castlemans disease. Blood 74, 1360-1367 (1989).
17. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Stills disease. Arthritis Rheum. 46, 3388-3389 (2002).
18. Sato K, Tsuchiya, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
19. Yokota S, Miyame T, Imagawa T et al Therapeutic effcacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818-825 (2005).
20. Yokota S, Imagawa T, Mori M et al Effcacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 371, 998-1006 (2008).
21. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52, 687-693 (2005).
22. Pascual V, Allantaz F, Arce E et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical aspect to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005).
23. Lurati A, Teruzzi B, Salmaso A et al Macrophage activation syndrome during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic-onset idiopathic juvenile arthritis. Paed. Rheumatol. Online 3, 79-85 (2005).
24. Lequerre T, Quarties F, Rosellini D et al Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308 (2008).
25. Petty RE, Southwood TR, Manners P et al International League of Association for Rheumatology. International League Association for Rheumatology classifcation of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390-392 (2004).
26. Zak M, Muller J, Karup Pedersen F. Final height, armspan, subischial leg length and body proportion in juvenile chronic arthritis: a long-term follow-up study. Horm. Res. 52, 80-85 (1999).
27. Nakajima S, Naruto T, Miyamae T, Imagawa T, Mori M, Nishimaki S, Yokota S. Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. Cytokine 47, 91-97 (2009).
28. Immonen K, Savolainen A, Kautiainen H, Hakala M. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J. Rheumatol. 35, 907-912 (2008).
29. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Pediatr. Suppl. 95, 38-41 (2005).
30. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum. 50, 689-698 (2004).
31. Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin. Padiatr. 221, 278-285 (2009).
32. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu. Rev. Immunol. 6, 485-512 (1988).
33. Hirano T. Interleukin-6 and its receptor: ten years later. Int. Rev. Immunol. 16, 249-284 (1998).
34. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797-819 (1997).
35. Leaman DW, Leung S, Li X, Stark GR. Regulation of STAT-dependent pathway by growth factors and cytokines. FASEB J. 10, 1578-1588 (1996).
36. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Ann. Rev. Immunol. 15, 797-819 (1997).
37. De Benedetti F, Pignati P, Gerloni V et al. Differences in synovial fuid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 24, 1403-1409 (1997).
38. Romanovsky AA, Almeida MC, Aronoff DM et al. Fever and hypothermia in systemic infammation: recent discoveries and revisions. Front. Biosci. 10, 2193-2216 (2005).
39. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J. Rheumatol. 28, 1670-1676 (2001).
40. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr. Opin Rheumatol. 15, 587-590 (2003).
41. Ravelli A, Caria MC, Buratti S et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 28, 865-867 (2001).
42. Bihl F, Emmenegger U, Reichen J et al Macrophage activation syndrome is associated with lobular hepatitis and severe duct injury with cholestasis. J. Hepatol. 44, 1208-1212 (2006).
43. Stabile A, Bertoni B, Ansuini V, La Torraca I, Salli A, Rigante D. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur. Rev. Med. Pharmacol. Sci. 10, 53-59 (2006).
44. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc. Natl Acad. Sci. USA 88, 4946-4950 (1991).
45. Aulitzky WE, Tilg H, Herold M, Berger M, Vogel W, Judmaier G. Enhanced serum levels of p-2-microglobulin, neopterin, and interferon-y in patients treated with recombinant tumor necrosis factor-a. J. Interferon Res. 8, 655-664 (1988).
46. Pucci B, Bertani F, Karpinich NO et al Detailing the role of Bax translocation, cytochrome c release, and perinuclear clustering of the mitochondria in the killing of HeLa cells by TNF. J. Cell. Physiol. 217, 442-449 (2008).
47. Soriano ME, Nicolosi L, Bernardi P. Desensitization of the permeability transition pore by cyclosporin a prevents activation of the mitochondrial apoptotic pathway and liver damage by tumor necrosis factor-a. J. Biol. Chem. 279, 36803-36808 (2004).
48. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J. Biol. Chem. 262(17), 8390-8394 (1987).
49. Romanovsky AA, Simons CT, Kulchitsky VA. 'Biphasic' fever often consist of more than two phases. Am. J. Physiol Regul Integr. Comp. Physiol. 275, R323-R331 (1998).
50. Takeuchi O, Hoshino K, Kawai T et al Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11, 443-451 (1999).
51. Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol. Behav. 89, 146-155 (2006).
52. Oka T, Oka K, Kobayashi T et al. Charcteristics of thermoregulatory and febrile responses in mice defant in prostaglandin EP1 and EP3 receptors. J. Physiol. 551, 945-954 (2003).
53. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J. Interferon Cytokine Res. 25, 241-253 (2005).
54. Jacober ML, Mamoni RL, Lima CS, Dos Anjos BL, Grotto HZ. Anaemia in patients with cancer: role of infammatory activity on iron metabolism and severity of anaemia. Med. Oncol. 24, 323-329 (2007).
55. Veldhuis GJ, Willemse PH, Mulder NH, Limburg PC, De Vries EG. Potential use of recombinant human interleukin-6 in clinical oncology. Leuk. Lymphoma 20, 373-379 (1996).
56. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 122, 78-86 (2009).
57. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr. Opin Rheumatol. 21, 224-230 (2009).
58. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK. IL-6 mediates hypoferremia of infammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271-1276 (2004).
59. Novick D, Engelmann H, Revel M, Leitner O, Rubinstein M. Monoclonal antibodies to the soluble human IL-6 receptor: affnity purifcation, ELISA, and inhibition of ligand binding. Hybridoma 10, 137-146 (1999).
60. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
61. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary defnition of improvement in juvenile arthritis. Arthritis Rheum. 40, 1202-1209 (1997).